ArticleJournal of gastrointestinal oncology2026
Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, especially in advanced or unresectable cases where traditional therapies often provide suboptimal outcomes. Transcatheter arterial chemoembolization (TACE) is a common treatment for intermediate-stage HCC but was limited by intra-tumoral hypoxia and immunosuppressive microenvironments. Integrating immunotherapy and anti-angiogenic agents could improve treatment efficacy. Tumor mutation burden (TMB) is a potential biomarker for predicting response to immunotherapy, yet, its impact on HCC remains underexplored. This study aimed to evaluate the prognostic significance of TMB in patients with unresectable HCC undergoing TACE combined with immunotherapy (camrelizumab) and anti-angiogenic drugs. Methods: This retrospective study analyzed 160 patients with unresectable HCC treated with TACE combined with immunotherapy (camrelizumab) and anti-angiogenic drugs. We stratified patients into high and low TMB groups based on a threshold of 10.025 mutations per megabase, determined through receiver operating characteristic (ROC) curve analysis. Outcomes evaluated included progression-free survival (PFS), overall survival (OS), and objective response rate (ORR), alongside adverse event incidence. Results: High TMB was associated with superior clinical outcomes, showing longer median PFS (8.98 Conclusions: TMB was a valuable prognostic biomarker for HCC patients undergoing TACE with immunotherapy and anti-angiogenic agents, correlating with enhanced survival and treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.